Cost-effectiveness of pharmacogenetics in anticoagulation: International differences in healthcare systems and costs

Pharmacogenomics

Volumn 13, Issue 12, 2012, Pages 1405-1417

  Verhoef, Talitha I ^a   Redekop, William K ^b   Van Schie, Rianne Mf ^a   Bayat, Samira ^a   Daly, Ann K ^c   Geitona, Mary ^d   Haschke Becher, Elisabeth ^e   Hughes, Dyfrig A ^f   Kamali, Farhad ^c   Levin, Lars Åke ^g   Manolopoulos, Vangelis G ^h   Pirmohamed, Munir ⁱ   Siebert, Uwe ^j,k,l,m   Stingl, Julia C ⁿ   Wadelius, Mia ^o   De Boer, Anthonius ^a   Maitland Van Der Zee, Anke Hilse ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF PELOPONNESE   (Greece)

^e ELISABETHINEN HOSPITAL   (Austria)

^f BANGOR UNIVERSITY   (United Kingdom)

^g LINKÖPING UNIVERSITY   (Sweden)

^h DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

ⁱ UNIVERSITY OF LIVERPOOL   (United Kingdom)

^j UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^k Oncotyrol Center for Personalized Cancer Medicine   (Austria)

^l HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ UNIVERSITY OF ULM   (Germany)

^o UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

acenocoumarol; atrial fibrillation; cost analysis; coumarins; health economics; healthcare system; phenprocoumon; warfarin

Indexed keywords

ACENOCOUMAROL; COUMARIN ANTICOAGULANT; CYTOCHROME P450 2C9; PHENPROCOUMON; WARFARIN;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COST EFFECTIVENESS ANALYSIS; CYP2C9 GENE; DRUG DOSE; DUODENUM BLEEDING; EUROPE; GASTROINTESTINAL HEMORRHAGE; GENE; GENOTYPE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PHARMACOGENETICS; REVIEW; STOMACH HEMORRHAGE; STROKE; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VKORC1 GENE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; GENOTYPE; HUMANS; PHARMACOGENETICS;

EID: 84866339466     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.124     Document Type: Review

References (86)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), S160-S198 (2008
2. Torn M, Cannegieter SC, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: A prospective study of 4202 patients. Arch. Intern. Med. 169(13), 1203-1209 (2009
3. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J. Clin. Pathol. 45(8), 704-706 (1992
4. Schalekamp T, de Boer A. Pharmacogenetics of oral anticoagulant therapy. Curr. Pharm. Des. 16(2), 187-203 (2010
5. van Schie RM, Wessels JA, le Cessie S et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur. Heart J. 32(15), 1909-1917 (2011
6. van Schie RM, Wadelius MI, Kamali F et al. Genotype-guided dosing of coumarin derivatives: The European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10), 1687-1695 (2009
7. French B, Joo J, Geller NL et al. Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11, 108 (2010
8. Higashi MK, Veenstra DL. Managed care in the genomics era: Assessing the cost effectiveness of genetic tests. Am. J. Managed Care 9(7), 493-500 (2003 (Pubitemid 36949536)
9. You JH, Chan FW, Wong RS, Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. Thromb. Haemost. 92(3), 590-597 (2004 (Pubitemid 39248016)
10. You JH, Tsui KK, Wong RS, Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin. Pharmacol. Ther. 86(5), 540-547 (2009
11. McWilliam A, Lutter R, Nardinelli C. Healthcare impact of personalized medicine using genetic testing: An exploratory analysis for warfarin. Per. Med. 5(3), 279-284 (2008 (Pubitemid 351819084)
12. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann. Inter. Med. 150(2), 73-83 (2009
13. Leey JA, McCabe S, Koch JA, Miles TP. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation. Am. J. Geriatr. Pharm. 7(4), 197-203 (2009
14. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes 2(5), 429-436 (2009
15. Schalekamp T, Boink GJ, Visser LE, Stricker BH, de Boer A, Klungel OH. CYP2C9 genotyping in acenocoumarol treatment: Is it a cost-effective addition to international normalized ratio monitoring? Clin. Pharml. Ther. 79(6), 511-520 (2006 (Pubitemid 43817947)
16. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacogenomics 28(1), 61-74 (2010
17. Connock M, Stevens C, Fry-Smith A et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: A systematic review and economic modelling. Health Technol. Assess. 11(38), iii-iv, ix-66 (2007
18. Ansell JE. Optimizing the efficacy and safety of oral anticoagulant therapy: High-quality dose management, anticoagulation clinics, and patient self-management. Semin. Vasc. Med. 3(3), 261-270 (2003
19. Ansell J, Hollowell J, Pengo V, Martinez- Brotons F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: The international study of anticoagulation management (ISAM). J. Thromb. Thrombolysis 23(2), 83-91 (2007 (Pubitemid 46416852)
20. Nichol MB, Knight TK, Dow T et al. Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: Comparison of anticoagulation clinic versus usual care. Ann. Pharmacother. 42(1), 62-70 (2008
21. Wallentin L, Yusuf S, Ezekowitz MD et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet 376(9745), 975-983 (2010
22. Verhoef TI, Redekop WK, Darba J et al. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics 11(7), 989-1002 (2010
23. D'Andrea G, D'Ambrosio RL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2), 645-649 (2005 (Pubitemid 40070748)
24. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 19(4), 422-437 (2010
25. Pengo V, Pegoraro C, Cucchini U, Iliceto S. Worldwide management of oral anticoagulant therapy: The ISAM study. J. Thromb. Thrombolysis 21(1), 73-77 (2006 (Pubitemid 43231132)
26. Jowett S, Bryan S, Mahe I et al. A multinational investigation of time and travelling costs in attending anticoagulation clinics. Value Health 11(2), 207-212 (2008 (Pubitemid 351473621)
27. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: A record linkage study in a large British population. Heart 91(4), 472-477 (2005 (Pubitemid 40432773)
28. Jorgensen AL, Al-Zubiedi S, Zhang JE et al. Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: A prospective study. Pharmacogenet. Genomics 19(10), 800-812 (2009
29. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb. Haemost. 106(5), 968-977 (2011
30. Gardiner C, Longair I, Pescott MA et al. Self-monitoring of oral anticoagulation: Does it work outside trial conditions? J. Clin. Pathol. 62(2), 168-171 (2009
31. Fitzmaurice DA, Murray ET, McCahon D et al. Self management of oral anticoagulation: Randomised trial. BMJ 331(7524), 1057 (2005
32. Rietbrock S, Heeley E, Plumb J, van Staa T. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am. Heart J. 156(1), 57-64 (2008 (Pubitemid 351877101)
33. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ 325(7368), 828-831 (2002
34. Abdelhafiz AH, Wheeldon NM. Use of resources and cost implications of stroke prophylaxis with warfarin for patients with nonvalvular atrial fibrillation. Am. J. Geriatr. Pharmacother. 1(2), 53-60 (2003 (Pubitemid 40410975)
35. Carroll K, Majeed A. Comorbidity associated with atrial fibrillation: A general practice-based study. Br. J. Gen. Pract. 51(472), 884-886, 889-891 (2001
36. Ericson L, Bergfeldt L, Bjorholt I. Atrial fibrillation: The cost of illness in Sweden. Eur. J. Health Econ. 12(5), 479-487 (2011
37. Wieloch M, Sjalander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: Reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur. Heart J. 32(18), 2282-2289 (2011
38. Wallvik J, Sjalander A, Johansson L, Bjuhr O, Jansson JH. Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand. J. Prim. Health Care 25(2), 123-128 (2007 (Pubitemid 46752224)
39. Nilsson GH, Bjorholt I, Krakau I. Anticoagulant treatment of patients with chronic atrial fibrillation in primary health care in Sweden - a retrospective study of incidence and quality in a registered population. Fam. Pract. 21(6), 612-616 (2004 (Pubitemid 39654857)
40. Andersson S, Bjorholt I, Nilsson GH, Krakau I. Resource consumption and management associated with monitoring of warfarin treatment in primary health care in Sweden. BMC Fam. Pract. 7, 67 (2006
41. Davidson T, Husberg M, Janzon M, Levin L. The cost of thromboembolic events and their prevention among patients with atrial fibrillation. J. Atr. Fibrillation 2(4), 870-880 (2011
42. Björholt I, Andersson S, Nilsson GH, Krakau I. The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden. BMC Fam. Pract. 8, 6 (2007
43. Lind M, Fahlen M, Kosiborod M, Eliasson B, Oden A. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb. Res. 129(1), 32-35 (2012
44. Lind M, Boman K, Johansson L et al. Thrombomodulin as a marker for bleeding complications during warfarin treatment. Arch. Intern. Med. 169(13), 1210-1215 (2009
45. Asberg S, Henriksson KM, Farahmand B, Terent A. Hemorrhage after ischemic stroke - relation to age and previous hemorrhage in a nationwide cohort of 58 868 patients. Int. J. Stroke doi:10.1111/j.1747-4949.2011.00718.x (2011) (Epub ahead of print
46. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: A report from the Swedish atrial fibrillation cohort study. Circulation 125(19), 2298-2307 (2012
47. Åsberg S. Outcome of stroke prevention: Analyses based on data from Riks-Stroke and other Swedish National Registers. Thesis, Uppsala University, Sweden (2012
48. Breukink-Engbers WG. Monitoring therapy with anticoagulants in The Netherlands. Semin. Thromb. Hemost. 25(1), 37-42 (1999 (Pubitemid 29202975)
49. Deuling JH, Vermeulen RP, Smit MD et al. Planning and monitoring of patients for electrical cardioversion for atrial fibrillation. Neth. Heart J. 20(4), 148-154 (2012
50. Torn M, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Risks of oral anticoagulant therapy with increasing age. Arch. Intern. Med. 165(13), 1527-1532 (2005 (Pubitemid 41058034)
51. Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, van den Besselaar AM, Sturk A, Rosendaal FR. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in The Netherlands: A randomized clinical trial. Arch. Intern. Med. 163(21), 2639-2646 (2003 (Pubitemid 37464423)
52. Visser LE, van Schaik RH, van Vliet M et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9.2 or CYP2C9.3 alleles on acenocoumarol or phenprocoumon. Thromb. Haemost. 92(1), 61-66 (2004 (Pubitemid 39010868)
53. Geitona M, Hollandezos M, Souliotis K, Athanasakis K, Kyriopoulos J. Cost-minimisation analysis of oral anticoagulant therapy monitoring methods: The case for prothrombin time self-monitoring. Hellenic J. Cardiol. 49(6), 388-396 (2008
54. Markatos CN, Grouzi E, Politou M et al. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 9(11), 1631-1638 (2008
55. Daskalopoulos ME, Daskalopoulou SS, Tzortzis E et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): A prospective randomized trial. Eur. J. Vasc. Endovasc. Surg. 29(6), 638-650 (2005 (Pubitemid 40614350)
56. Völler H, Braun S. Update of INR-selfmonitoring. Hamostaseologie 28(4), 231-233 (2008
57. Behr S, Andersohn F, Garbe E. Risk of intracerebral hemorrhage associated with phenprocoumon exposure: A nested case-control study in a large population-based German database. Pharmacoepidemiol. Drug Saf. 19(7), 722-730 (2010
58. McBride D, Mattenklotz AM, Willich SN, Bruggenjurgen B. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. Value Health 12(2), 293-301 (2009
59. McBride D, Bruggenjurgen B, Roll S, Willich SN. Anticoagulation treatment for the reduction of stroke in atrial fibrillation: A cohort study to examine the gap between guidelines and routine medical practice. J. Thromb. Thrombolysis 24(1), 65-72 (2007 (Pubitemid 46838499)
60. Voller H, Glatz J, Taborski U, Bernardo A, Dovifat C, Heidinger K. Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study). Z. Kardiol. 94(3), 182-186 (2005 (Pubitemid 40394900)
61. Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U; SPOG 60+ Study Group. Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial. Thromb. Haemost. 100(6), 1089-1098 (2008
62. Oertel LB, Libby EN. Is patient self-testing a good thing? J. Thromb. Thrombolysis 29(2), 214-218 (2010
63. Heneghan C, Ward A, Perera R et al. Self-monitoring of oral anticoagulation: Systematic review and meta-analysis of individual patient data. Lancet 379(9813), 322-334 (2012
64. Jobski K, Behr S, Garbe E. Drug interactions with phenprocoumon and the risk of serious haemorrhage: A nested case-control study in a large population-based German database. Eur. J. Clin. Pharmacol. 67(9), 941-951 (2011
65. Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U. Self-management of oral anticoagulation in the elderly: Rationale, design, baselines and oral anticoagulation control after one year of follow-up. A randomized controlled trial. Thromb. Haemost. 97(3), 408-416 (2007 (Pubitemid 46437803)
66. Ali A, Bailey C, Abdelhafiz AH. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis. Age Ageing doi:10.1093/ageing/ afs017 (2012) (Epub ahead of print
67. Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: Quantitative benefit-harm and economic analyses. BMJ 343, D6333 (2011
68. Jowett S, Bryan S, Mant J et al. Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation. Stroke 42(6), 1717-1721 (2011
69. Kansal AR, Sorensen SV, Gani R et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 98(7), 573-578 (2012
70. Hemingway H, Henriksson M, Chen R et al. The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: A systematic review and decision model. Health Technol. Assess. 14(9), 1-151, iii-iv (2010
71. de Leest H, van Dieten H, van Tulder M, Lems WF, Dijkmans BA, Boers M. Costs of treating bleeding and perforated peptic ulcers in The Netherlands. J. Rheumatol. 31(4), 788-791 (2004 (Pubitemid 38451270)
72. Roos YB, Dijkgraaf MG, Albrecht KW et al. Direct costs of modern treatment of aneurysmal subarachnoid hemorrhage in the first year after diagnosis. Stroke 33(6), 1595-1599 (2002 (Pubitemid 34619964)
73. Ten Cate-Hoek AJ, Toll DB, Buller HR et al. Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual. J. Thromb. Haemost. 7(12), 2042-2049 (2009
74. Struijs JN, van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. Future costs of stroke in The Netherlands: The impact of stroke services. Int. J. Technol. Assess. Health Care 22(4), 518-524 (2006 (Pubitemid 44622974)
75. Gioldasis G, Talelli P, Chroni E, Daouli J, Papapetropoulos T, Ellul J. In-hospital direct cost of acute ischemic and hemorrhagic stroke in Greece. Acta Neurol. Scand. 118(4), 268-274 (2008
76. Maniadakis N, Ekman M, Fragoulakis V, Papagiannopoulou V, Yfantopoulos J. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. Eur. J. Health Econ. 12(3), 253-261 (2011
77. Reinhold T, Rosenfeld S, Muller- Riemenschneider F et al. Patients suffering from atrial fibrillation in Germany: Characteristics, resource consumption and costs. Herz doi:10.1007/s00059-011-3575-8 (2012) (Epub ahead of print
78. Weimar C, Weber C, Wagner M et al. Management patterns and health care use after intracerebral hemorrhage. A cost-of-illness study from a societal perspective in Germany. Cerebrovasc. Dis. 15(1-2), 29-36 (2003 (Pubitemid 36131895)
79. Brüggenjürgen B, Rossnagel K, Roll S et al. The impact of atrial fibrillation on the cost of stroke: The Bberlin acute stroke study. Value Health 10(2), 137-143 (2007 (Pubitemid 46481140)
80. Kolominsky-Rabas PL, Heuschmann PU, Marschall D et al. Lifetime cost of ischemic stroke in Germany: Results and national projections from a population-based stroke registry: The Erlangen Stroke Project. Stroke 37(5), 1179-1183 (2006 (Pubitemid 43731858)
81. Wancata J, Sobocki P, Katschnig H. Cost of disorders of the brain in Europe Study Group: Cost of disorders of the brain in Austria in the year 2004. Wien. Klin. Wochenschr. 119(3-4), 91-98 (2007 (Pubitemid 46972245)
82. Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacogenomics 21(9), 651-659 (2003 (Pubitemid 36808216)
83. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139-1151 (2009
84. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883-891 (2011
85. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 123(22), 2562-2570 (2011
86. You JH, Tsui KK, Wong RS, Cheng G. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PLoS ONE 7(6), e39640 (2012